JacekPinskiMD

Oncology • Los Angeles, CA

Associate Professor, Medicine, USC School of Medicine

Join to view full profile

Dr. Pinski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pinski's full profile

Already have an account?

Office
1441 Eastlake Ave
Ste 8302E
Los Angeles, CA 90089
Phone+1 323-865-3000

Fax+1 323-865-0061

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2001
Ochsner Clinic FoundationResidency, Internal Medicine, 1996 - 1998
Goethe University Frankfurt Medical FacultyClass of 1988

Certifications & Licensure

CA State Medical License 2002 - 2026
MD State Medical License 1999 - 2001
American Board of Internal Medicine Medical Oncology

Clinical Trials

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Withdrawn
Phase 2
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors Start of enrollment: 2006 Nov 01
Completed
Phase 1
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2007 Apr 01
Completed
Phase 2
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2010 Nov 02
Completed
Phase 1, Phase 2
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 2
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel Start of enrollment: 2012 Jul 01
Terminated
Phase 2
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer Start of enrollment: 2016 Mar 01
Terminated
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer Start of enrollment: 2018 Aug 30
Withdrawn
Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures Start of enrollment: 2022 Mar 01
Recruiting
Not Applicable
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer Start of enrollment: 2015 Sep 08
Active, not recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Amir Goldkorn, Catherine Tangen, Melissa Plets, Daniel Bsteh, Tong Xu
JAMA Network Open. 2024-10-01
34 citations
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.
Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek Pinski, David I. Quinn
Prostate Cancer and Prostatic Diseases. 2021-03-01
19 citations
Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate-sensitive prostate cancer (SWOG S1216)
Amir Goldkorn, Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha
Clinical Cancer Research. 2021-01-26

Press Mentions

USC Doctors Use Power of Poetry to Help Cancer Patients Heal: 'We Want This Movement to Spread'January 24th, 2022
Cell BT (CBI) Announces Appointment of Joshua Ofman, M.D., MSHS, to Board of DirectorsJuly 9th, 2019
Presentation in Prostate Cancer at 2017 Genitourinary Cancers SymposiumMarch 6th, 2017